Serina Therapeutics, Inc. Accrued Liabilities, Current
Serina Therapeutics, Inc. (SER) had Accrued Liabilities, Current of $1.36 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Accrued Liabilities, Current $1.36M.
- 2026-03-31: Accrued Liabilities, Current $1.51M.
- 2025-12-31: Accrued Liabilities, Current $1.21M.
- 2025-09-30: Accrued Liabilities, Current $1.14M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.36M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $1.51M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $1.21M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $1.14M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $1.31M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $979.00K 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.43M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $1.16M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $320.00K 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $1.30M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $583.00K 10-K · filed 2025-03-24 | $529.00K 10-K · filed 2024-03-22 |
| 2023-09-30 | $293.00K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $256.00K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $359.00K 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $273.00K 10-K · filed 2024-03-22 | |
| 2021-12-31 | $366.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |